The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating tumor DNA in Chinese Patients with Non-Small Cell Lung Cancer

Here, we drew and compared the somatic mutational profile using circulating tumor DNA (ctDNA) and tumor tissue sequence analysis in lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), and assess its potential clinical value. In this study, 221 tumor tissues and 174 plasma samples from non-small cell lung cancer (NSCLC) patients were analyzed by hybridization capture-based next-generation sequencing (NGS) panel including 95 cancer-associated genes. Tumor response assessments were applied to 137 patients with advanced-stage (III and IV) NSCLC who firstly received targeted agents. As a promising alternative for tumor genomic profiling, ctDNA analysis is more credible in LUAD than in LUSC. Genomic subtyping has strong potential in prognostication and therapeutic decision-making for NSCLC patients, which indicated the necessity for the utility of target NGS in guiding clinical management.